Filter posts

#BIO2019: Taking the Pulse of Dealmakers: 2019 Outlook

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year …

Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical ...

In his State of the Union address, President Trump called on Congress to “do more” …

Market Outlook—Leveraging Market Corrections for M&A or IPOs

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year …

#BIOCEO19 Kicks Off in NYC

Pharmaceutical innovation is not slowing down. Last year the FDA approved a total of 59 …

What's New at #BIOWC19?

In case you missed it, the 2019 BIO World Congress on Industrial Biotechnology is headed …

It Starts with One—Partnering Meeting Leads to Unique Public-Private Partnership

Roy Zwahlen took a long shot when he requested a meeting with an investment firm …

2018 BIO Investor Forum Wraps Up

As the stock market continued its volatile swings this week, investors at the BIO Investor …

Investment Market Good for Deal-making at #BIF18

As we move into the final quarter of 2018, we reflect on a year with …

Digital Health Innovation to be Spotlighted at the BIO Investor Forum

Is your company trying to expand into “digiceuticals” or digital therapeutics? Are you looking to …

The Patient Perspective-Valuable for Drug Development

Congress, the Food and Drug Administration (FDA), drug developers, researchers and patient groups have all …